1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

Atenolol: From Heart Health Hero to Global Pharmaceutical Leader

Admin
20 June 2024

Atenolol is a commonly prescribed drug in the beta-blocker class. It is primarily used to treat hypertension (high blood pressure) and angina pectoris (chest pain due to reduced blood flow to the heart). Known for its effectiveness and relatively mild side effect profile, atenolol has been an integral part of cardiovascular medicine since its introduction. In this blog, we are going to explore different aspects of atenolol, R & D, global market size, market drivers, API manufacturing, etc.

Let's explore the different aspects of atenolol:-

Pharmaceutical Research and Development

Atenolol's journey from its initial discovery to its widespread use today involved extensive research and clinical trials. Developed in the 1970s, the drug was intended to selectively block beta-adrenergic receptors in the heart and blood vessels, leading to a reduction in heart rate and blood pressure. Research is continuing to examine its effectiveness in treating other conditions beyond its primary indication.

Atenolol Drug Development

Atenolol drug development involves a rigorous process to ensure safety, efficacy, and compliance with regulatory standards. From the synthesis of active pharmaceutical ingredients (APIs) to formulation into tablets and capsules, pharmaceutical companies adhere to Good Manufacturing Practices (GMP) to produce high-quality medicines. Development also involves clinical trials to determine the therapeutic benefits and safety profile of the drug.

Market Insights

The global market size of atenolol is expected to grow at a compound annual growth rate of approximately 5% from 2023 to 2035. The market is expected to reach USD 28 billion by the end of 2035, up from approximately USD 11 billion in 2022. (Courtesy of Globe News Wire)

Key players

Key players in the atenolol market include Abbott Laboratories, F. Hoffmann-La Roche AG, Danaher Corporation, Bio-Rad Laboratories, Inc., Sysmex Corporation, Zydus Pharmaceuticals Inc., Ipca Laboratories Limited, and Siemens Healthineers AG.

• Market Drivers

Increasing incidence of heart diseases, including hypertension, is driving the demand for atenolol.
Unhealthy lifestyles, such as improper diet and sedentary behavior, contribute to heart disease. The number of geriatric patients is increasing across the globe, further boosting the market growth.

Regional Trends:

Europe is expected to witness the highest growth in the atenolol market.
North America is also expected to see significant growth.
Cardiovascular diseases remain a global problem, driving the use of atenolol.

API Manufacturers:

Several manufacturers across the globe are involved in the production of atenolol active pharmaceutical ingredients (API). India is a leading country in API manufacturing. Companies such as Alembic Pharmaceuticals, Aurobindo Pharma, and Cadila Healthcare manufacture Atenolol API.

- Other countries such as China, Japan, and South Korea have also made significant contributions.

Sustainable Synthesis:

Atenolol faces challenges due to inefficient and environmentally harmful synthesis methods.
Traditional synthesis generates large amounts of waste and by-products.
Researchers are studying sustainable approaches to produce Atenolol more efficiently.

Future Outlook:

With the aging of the world population, the demand for cardiovascular drugs will continue to increase.
Atenolol's role in treating heart disease remains critical.
Research and innovation drive improvements in drug development and synthesis.

Chemxpert Database:

Chemxpert database provides insights into pharmaceutical manufacturing and provides data on customers, suppliers, market size, clinical trials, regulatory insights, and pricing mechanisms of atenolol. This valuable resource helps you make decisions, forecast market trends, and understand the competitive landscape.

Conclusion

In summary, atenolol plays a vital role in cardiovascular health and its market growth reflects the increasing need for effective treatment. Researchers and manufacturers continue to explore sustainable ways to improve its production and effectiveness.